Afirma Molecular Testing: Unique Situations and New Prognostic Development

Thyroid nodules are common, with a significant proportion presenting with indeterminate cytology following fine-needle aspiration (FNA). The Bethesda System for Reporting Thyroid Cytopathology categories III (atypia of undetermined significance or follicular lesion of undetermined significance, AUS/FLUS) and IV (follicular neoplasm or suspicious for follicular neoplasm, FN/SFN) represent this indeterminate group. Historically, these categories often necessitated diagnostic surgery, such as lobectomy, to rule out malignancy. However, a substantial number of these surgically resected nodules prove to be benign, exposing patients to surgical risks and costs without therapeutic benefit.

Afirma molecular testing (Veracyte, Inc.) was developed to address this diagnostic gap. It analyzes gene expression classifiers (GEC) from FNA samples to identify benign nodules within the indeterminate categories, thereby potentially reducing the rate of diagnostic surgeries. The initial Afirma GEC assay was designed to classify nodules as either benign or suspicious. A benign result indicates a low probability of malignancy, allowing for surveillance rather than immediate surgery. A suspicious result suggests a higher probability of malignancy, supporting a recommendation for surgical intervention.

Expanding Utility and Prognostic Development

The utility of Afirma testing extends to specific clinical situations where traditional cytological assessment may be particularly challenging or where patient factors influence management decisions. These unique situations can include nodules with equivocal cytological features, multifocal nodules, or nodules in patients with a history of radiation exposure. In such cases, the objective molecular data provided by Afirma can offer additional clarity, guiding clinicians toward more informed management strategies. For instance, a benign Afirma result in a patient with a history of head and neck radiation, where the risk of malignancy is generally elevated, could still support a conservative approach, avoiding unnecessary surgery.

Recent advancements, as discussed at endo 2026, include the development of new prognostic markers within the Afirma platform. These markers are intended to provide more granular risk stratification for nodules that are classified as suspicious by the initial GEC. While the primary GEC focuses on distinguishing benign from suspicious, the new prognostic developments aim to differentiate between low-risk and high-risk malignancies, or to predict the aggressiveness of a detected cancer. This enhanced prognostic information could influence the extent of initial surgery (e.g., lobectomy versus total thyroidectomy) or guide decisions regarding adjuvant therapies and surveillance intensity. For example, a suspicious nodule with molecular features indicating a low-risk, indolent malignancy might be managed with a less aggressive surgical approach compared to a suspicious nodule with markers suggesting a more aggressive variant of thyroid cancer. This evolution in molecular testing moves beyond a simple benign/suspicious dichotomy to offer a more nuanced understanding of a nodule's biological potential, aligning management with the specific risk profile of the patient's disease.